- Corporate Officers - B
- Behbahani Ali
Insider Trading History of Behbahani Ali
The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Behbahani Ali since 2018.
This trader's CIK number is 1613867.
At the time of last reporting, Behbahani Ali was the Officer of Adaptimmune Therapeutics Plc. (stock ticker symbol ADAP).
Also see all insider trading activities at Adaptimmune Therapeutics Plc.
Note that in the past
Behbahani Ali also reported insider trading activities as an insider of the following companies:
Yearly summary of insider trading at Akouos, Inc. (AKUS) by Behbahani Ali
| | Insider Buying | Insider Sales | Option Exercises |
---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
---|
2020 | AKUS | 588,235 | $9,999,995 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Savara Inc (SVRA) by Behbahani Ali
| | Insider Buying | Insider Sales | Option Exercises |
---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
---|
2023 | SVRA | 333,333 | $999,999 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Black Diamond Therapeutics, Inc. (BDTX) by Behbahani Ali
| | Insider Buying | Insider Sales | Option Exercises |
---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
---|
2020 | BDTX | 800,000 | $15,200,000 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Mbx Biosciences, Inc. (MBX) by Behbahani Ali
| | Insider Buying | Insider Sales | Option Exercises |
---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
---|
2024 | MBX | 500,000 | $8,000,000 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Adaptimmune Therapeutics Plc (ADAP) by Behbahani Ali
| | Insider Buying | Insider Sales | Option Exercises |
---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
---|
2025 | ADAP | 0 | $0 | 19,500,000 | $229,171 | 0 | $0 |
2020 | ADAP | 7,500,000 | $5,002,500 | 0 | $0 | 0 | $0 |
2018 | ADAP | 12,000,000 | $20,004,000 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Genocea Biosciences, Inc. (GNCA) by Behbahani Ali
| | Insider Buying | Insider Sales | Option Exercises |
---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
---|
2022 | GNCA | 0 | $0 | 10,376,936 | $750,066 | 0 | $0 |
2020 | GNCA | 3,151,260 | $7,090,335 | 0 | $0 | 0 | $0 |
2019 | GNCA | 12,805,411 | $14,685,631 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Trevi Therapeutics, Inc. (TRVI) by Behbahani Ali
| | Insider Buying | Insider Sales | Option Exercises |
---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
---|
2022 | TRVI | 3,580,526 | $6,802,999 | 0 | $0 | 0 | $0 |
2021 | TRVI | 1,851,852 | $0 | 0 | $0 | 0 | $0 |
2020 | TRVI | 0 | $0 | 564 | $1,500 | 0 | $0 |
2019 | TRVI | 2,500,000 | $25,000,000 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Cvrx, Inc. (CVRX) by Behbahani Ali
| | Insider Buying | Insider Sales | Option Exercises |
---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
---|
2023 | CVRX | 0 | $0 | 0 | $0 | 316 | $74 |
Yearly summary of insider trading at Regulus Therapeutics Inc. (RGLS) by Behbahani Ali
| | Insider Buying | Insider Sales | Option Exercises |
---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
---|
2020 | RGLS | 4,398,602 | $2,735,930 | 0 | $0 | 0 | $0 |
2019 | RGLS | 1,136,704 | $1,227,640 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Marker Therapeutics, Inc. (MRKR) by Behbahani Ali
| | Insider Buying | Insider Sales | Option Exercises |
---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
---|
2021 | MRKR | 5,714,285 | $9,999,998 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Mirum Pharmaceuticals, Inc. (MIRM) by Behbahani Ali
| | Insider Buying | Insider Sales | Option Exercises |
---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
---|
2019 | MIRM | 450,000 | $6,750,000 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Metacrine, Inc. (MTCR) by Behbahani Ali
| | Insider Buying | Insider Sales | Option Exercises |
---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
---|
2021 | MTCR | 0 | $0 | 497,270 | $489,102 | 0 | $0 |
2020 | MTCR | 769,230 | $9,999,990 | 0 | $0 | 0 | $0 |
Insider trading activities at 12 companies by Behbahani Ali:
1. Akouos, Inc. (AKUS)
2. Savara Inc (SVRA)
3. Black Diamond Therapeutics, Inc. (BDTX)
4. Mbx Biosciences, Inc. (MBX)
5. Adaptimmune Therapeutics Plc (ADAP)
6. Genocea Biosciences, Inc. (GNCA)
7. Trevi Therapeutics, Inc. (TRVI)
8. Cvrx, Inc. (CVRX)
9. Regulus Therapeutics Inc. (RGLS)
10. Marker Therapeutics, Inc. (MRKR)
11. Mirum Pharmaceuticals, Inc. (MIRM)
12. Metacrine, Inc. (MTCR)
Table 1. Insider trading of Akouos, Inc. (AKUS) by Behbahani Ali
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|
2020-06-30 | AKUS | Buy | 588,235 | 17.00 | 9,999,995 |
Table 2. Insider trading of Savara Inc (SVRA) by Behbahani Ali
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|
2023-07-17 | SVRA | Buy | 333,333 | 3.00 | 999,999 |
Table 3. Insider trading of Black Diamond Therapeutics, Inc. (BDTX) by Behbahani Ali
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|
2020-02-03 | BDTX | Buy | 800,000 | 19.00 | 15,200,000 |
Table 4. Insider trading of Mbx Biosciences, Inc. (MBX) by Behbahani Ali
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|
2024-09-16 | MBX | Buy | 500,000 | 16.00 | 8,000,000 |
Table 5. Insider trading of Adaptimmune Therapeutics Plc (ADAP) by Behbahani Ali
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|
2025-08-18 | ADAP | Sale | 14,671,794 | .01 | 176,061 |
2025-08-15 | ADAP | Sale | 4,828,206 | .01 | 53,110 |
2020-01-24 | ADAP | Buy | 7,500,000 | .67 | 5,002,500 |
2018-09-07 | ADAP | Buy | 12,000,000 | 1.67 | 20,004,000 |
Table 6. Insider trading of Genocea Biosciences, Inc. (GNCA) by Behbahani Ali
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|
2022-05-25 | GNCA | Sale | 4,445,093 | .08 | 364,497 |
2022-05-24 | GNCA | Sale | 5,931,843 | .07 | 385,569 |
2020-07-24 | GNCA | Buy | 3,151,260 | 2.25 | 7,090,335 |
2019-06-24 | GNCA | Buy | 2,857,142 | 3.50 | 9,999,997 |
2019-02-14 | GNCA | Buy | 9,948,269 | .47 | 4,685,634 |
Table 7. Insider trading of Trevi Therapeutics, Inc. (TRVI) by Behbahani Ali
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|
2022-04-11 | TRVI | Buy | 3,580,526 | 1.90 | 6,802,999 |
2021-10-18 | TRVI | Buy | 1,851,852 | .00 | 0 |
2020-04-03 | TRVI | Sale | 564 | 2.66 | 1,500 |
2019-05-09 | TRVI | Buy | 2,500,000 | 10.00 | 25,000,000 |
Table 8. Insider trading of Cvrx, Inc. (CVRX) by Behbahani Ali
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|
2023-12-14 | CVRX | Option Ex | 316 | .24 | 74 |
Table 9. Insider trading of Regulus Therapeutics Inc. (RGLS) by Behbahani Ali
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|
2020-12-04 | RGLS | Buy | 4,398,602 | .62 | 2,735,930 |
2019-05-07 | RGLS | Buy | 1,136,704 | 1.08 | 1,227,640 |
Table 10. Insider trading of Marker Therapeutics, Inc. (MRKR) by Behbahani Ali
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|
2021-03-16 | MRKR | Buy | 5,714,285 | 1.75 | 9,999,998 |
Table 11. Insider trading of Mirum Pharmaceuticals, Inc. (MIRM) by Behbahani Ali
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|
2019-07-22 | MIRM | Buy | 450,000 | 15.00 | 6,750,000 |
Table 12. Insider trading of Metacrine, Inc. (MTCR) by Behbahani Ali
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|
2021-12-10 | MTCR | Sale | 37,570 | 1.32 | 49,629 |
2021-12-22 | MTCR | Sale | 459,700 | .96 | 439,473 |
2020-09-18 | MTCR | Buy | 769,230 | 13.00 | 9,999,990 |
Insider trading activities including stock purchases, stock sales, and option exercises
listed in the above table cannot be completely guaranteed as to their accuracy.
For more information regarding the trades made by Behbahani Ali
(Officer of Adaptimmune Therapeutics Plc at the time of this reporting) see
the Securities and Exchange Commission (SEC) website.